{"id":"NCT00502996","sponsor":"Hoffmann-La Roche","briefTitle":"A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.","officialTitle":"Multicenter Non-Comparative Expanded Access Program of to Assess Safety of Rituximab (Mab Anti Cd-20) in Patients With Rheumatoid Arthritis (Ser)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2007-07-18","resultsPosted":"2016-10-14","lastUpdate":"2016-10-14"},"enrollment":246,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Methotrexate","otherNames":[]},{"type":"DRUG","name":"rituximab [MabThera/Rituxan]","otherNames":[]}],"arms":[{"label":"Rituximab","type":"EXPERIMENTAL"}],"summary":"This single arm study will assess the safety of MabThera plus methotrexate in patients with rheumatoid arthritis who have had a lack of response to 1-5 DMARDs or biological agents. Patients will receive MabThera (1g i.v.) on days 1 and 15, concomitantly with methotrexate \\>=15mg p.o./week. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.","primaryOutcome":{"measure":"Number of Participants With Any Adverse Event, Any Serious Adverse Event, and Death","timeFrame":"Up to Week 48","effectByArm":[{"arm":"Rituximab","deltaMin":189,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":49,"countries":["Argentina","Brazil","Chile","Colombia","Ecuador","El Salvador","Mexico","Peru","Uruguay","Venezuela"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":232},"commonTop":["Headache","Urinary tract infection","Nausea","Dizziness","Diarrhea"]}}